<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03137186</url>
  </required_header>
  <id_info>
    <org_study_id>Mansmed trial I</org_study_id>
    <nct_id>NCT03137186</nct_id>
  </id_info>
  <brief_title>Repurposing Metformin as Anticancer Drug: in Advanced Prostate Cancer</brief_title>
  <acronym>Mansmed</acronym>
  <official_title>Mansmed Trial : Repurposing Metformin as Anticancer Drug, RCT in Advanced Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluate the addition of metformin to standard of care in locally advanced and
      metastatic prostate cancer, half the patient will receive metformin in combination with
      standard treatment, and the other half will receive the standard of care only
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Advanced-stage PCa is usually treated with androgen-deprivation therapy (ADT). Most patients
      with metastatic disease who were managed with ADT eventually progress to castration-resistant
      prostate cancer (CRPC) and die of the disease. CRPC can be treated with docetaxel,
      abiraterone plus prednisone, enzalutamide, and cabazitaxel, which provide limited survival
      benefits. Thus, there is still a need to improve the therapeutic options available for
      advanced-stage prostate cancer patients. Targeting therapy-resistant cancer stem cells (CSCs
      )in prostate cancer provides a unique opportunity for novel therapeutic interventions.

      Metformin, a common well-tolerated oral biguanide prescribed for type II diabetes, could be
      used to sensitize prostate CSCs to current conventional anticancer therapies and improve the
      efficacy of treatment. Some studies reported that Metformin could enhance the effectiveness
      of ADT. Metformin augmented the antiproliferative and apoptotic effects of ADT in prostate
      cancer. The combination of these two drugs significantly reduces prostate cancer cell growth
      compared to monotherapy with either drug. Also, metformin might reduce the development of
      CRPC.

      Many studies showed that obesity and DM were linked to aggressive prostate cancer phenotype,
      including biochemical failure after radical prostatectomy and external beam radiotherapy with
      higher incidence of complications of ADT. Interestingly, metformin reduces the incidence of
      diabetes and the adverse metabolic effects of ADT, including hyperinsulinaemia and
      dyslipidaemia, and decreases myocardial infarction risk and prolongs survival in diabetic
      patients.

      To the best of our knowledge, after extensive computer research, there is no published
      results from prospective randomized trials evaluating role of metformin among men with high
      risk locally advanced or metastatic prostate cancer patients who will start treatment with
      ADT.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>duration in months from beginning of treatment till development of CRPC</measure>
    <time_frame>2 years</time_frame>
    <description>time till development of CRPC [Castrate resistant prostate cancer], is defined by disease progression despite androgen depletion therapy (ADT) and may present as either a continuous rise in serum prostate-specific antigen (PSA) levels, the progression of pre-existing disease, and/or the appearance of new metastases.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CRPC free survival</measure>
    <time_frame>4 years</time_frame>
    <description>Number of survivors without CRPC at 4 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall patients` survival</measure>
    <time_frame>4 years</time_frame>
    <description>Number of overall survivors at 4 years regardless occurrence of CRPC or not</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Investigational arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin will be added to standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will treated according to Standard of care only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin will be added as a daily treatment to the standard treatment in both neoadjuvant and adjuvant settings of locally advanced cases and lifelong to metastatic cases. The starting daily dose of metformin is 850mg Once daily, to be increased to 850 mg if tolerated</description>
    <arm_group_label>Investigational arm</arm_group_label>
    <other_name>Cidophage</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. High-risk newly diagnosed non-metastatic node-negative disease at least two of:

               -  Stage T3/4, PSA≥40ng/ml or Gleason sum score 8-10

               -  Intention to treat with radical radiotherapy (unless there is a contraindication)

          2. OR newly diagnosed metastatic or node-positive disease at least one of:

               -  Stage T any N+ M0

               -  Stage T any Nany M+

          3. OR previously treated with radical surgery and/or radiotherapy, now relapsing

             At least one of:

             (-PSA ≥4ng/ml and rising with doubling time less than 6 months,N+, M+)

          4. And for all patients

               -  Age &gt; 18 years

               -  Histologically confirmed prostate adenocarcinoma

               -  Intention to treat with long-term androgen deprivation therapy

               -  Fit for all protocol treatment and follow-up, ECOG performance status 0-2

               -  Diabetic and non-diabetic patients

               -  Patients with adequate organ function(AST - ALAT ≤ 2.5x ULN,Bilirubin ≤ 1.5 x
                  ULN)

        Exclusion Criteria:

          1. Age &lt; 18 years

          2. Excessive alcohol intake, acute or chronic

          3. Patients already treated with Metformin or an analoge

          4. Known hypersensitivity or allergy to Metformin or any of the excipients.

          5. Patients with a history of lactic acidosis

          6. Patient treated for a cancer other than prostate cancer, with the exception of basal
             cell carcinoma

          7. Acute or chronic metabolic acidosis.

          8. Patients suffering from severe dehydration.

          9. Patients with chronic heart failure.

         10. Patients with hepatic impairment.

         11. Patients with severe renal disease.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reham Alghandour</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reham Alghandour</last_name>
    <phone>01002682875</phone>
    <email>Rehamalghandour@mans.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ahmed Elshaal</last_name>
    <phone>01001855490</phone>
    <email>Elshalam@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mansoura university</name>
      <address>
        <city>Mansourah</city>
        <zip>35516</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reham Alghandour</last_name>
      <phone>00201002682875</phone>
      <email>Rema-200@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ahmed Elshaal</last_name>
      <phone>00201001855490</phone>
      <email>Elshalam@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <results_reference>
    <citation>Colquhoun AJ, Venier NA, Vandersluis AD, Besla R, Sugar LM, Kiss A, Fleshner NE, Pollak M, Klotz LH, Venkateswaran V. Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer. Prostate Cancer Prostatic Dis. 2012 Dec;15(4):346-52. doi: 10.1038/pcan.2012.16. Epub 2012 May 22.</citation>
    <PMID>22614062</PMID>
  </results_reference>
  <results_reference>
    <citation>Dowling RJ, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Med. 2011 Apr 6;9:33. doi: 10.1186/1741-7015-9-33. Review.</citation>
    <PMID>21470407</PMID>
  </results_reference>
  <results_reference>
    <citation>Eriksson A, Attvall S, Bonnier M, Eriksson JW, Rosander B, Karlsson FA. Short-term effects of metformin in type 2 diabetes. Diabetes Obes Metab. 2007 Jul;9(4):483-9.</citation>
    <PMID>17587390</PMID>
  </results_reference>
  <results_reference>
    <citation>Hamilton RJ. Metformin for castrate-resistant prostate cancer: learning more about an old dog's new tricks. Eur Urol. 2014 Sep;66(3):475-7; discussion 477-8. doi: 10.1016/j.eururo.2014.01.013. Epub 2014 Jan 23.</citation>
    <PMID>24472709</PMID>
  </results_reference>
  <results_reference>
    <citation>Hankinson SJ, Fam M, Patel NN. A review for clinicians: Prostate cancer and the antineoplastic properties of metformin. Urol Oncol. 2017 Jan;35(1):21-29. doi: 10.1016/j.urolonc.2016.10.009. Epub 2016 Nov 9. Review.</citation>
    <PMID>27836248</PMID>
  </results_reference>
  <results_reference>
    <citation>Mayer MJ, Klotz LH, Venkateswaran V. Metformin and prostate cancer stem cells: a novel therapeutic target. Prostate Cancer Prostatic Dis. 2015 Dec;18(4):303-9. doi: 10.1038/pcan.2015.35. Epub 2015 Jul 28. Review.</citation>
    <PMID>26215782</PMID>
  </results_reference>
  <results_reference>
    <citation>Ranasinghe WK, Sengupta S, Williams S, Chang M, Shulkes A, Bolton DM, Baldwin G, Patel O. The effects of nonspecific HIF1α inhibitors on development of castrate resistance and metastases in prostate cancer. Cancer Med. 2014 Apr;3(2):245-51. doi: 10.1002/cam4.189. Epub 2014 Jan 27.</citation>
    <PMID>24464861</PMID>
  </results_reference>
  <results_reference>
    <citation>Rothermundt C, Hayoz S, Templeton AJ, Winterhalder R, Strebel RT, Bärtschi D, Pollak M, Lui L, Endt K, Schiess R, Rüschoff JH, Cathomas R, Gillessen S. Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09). Eur Urol. 2014 Sep;66(3):468-74. doi: 10.1016/j.eururo.2013.12.057. Epub 2014 Jan 4.</citation>
    <PMID>24412228</PMID>
  </results_reference>
  <results_reference>
    <citation>Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol. 2009 May;181(5):1998-2006; discussion 2007-8. doi: 10.1016/j.juro.2009.01.047. Epub 2009 Mar 14. Review.</citation>
    <PMID>19286225</PMID>
  </results_reference>
  <results_reference>
    <citation>Song CW, Lee H, Dings RP, Williams B, Powers J, Santos TD, Choi BH, Park HJ. Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. Sci Rep. 2012;2:362. doi: 10.1038/srep00362. Epub 2012 Apr 12.</citation>
    <PMID>22500211</PMID>
  </results_reference>
  <results_reference>
    <citation>Spratt DE, Zhang Z, Zelefsky MJ. Reply to Leah Bensimon, Samy Suissa, and Laurent Azoulay's letter to the editor re: Daniel E. Spratt, Chi Zhang, Zachary S. Zumsteg, Xin Pei, Zhigang Zhang, Michael J. Zelefsky. metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol 2013;63:709-16. Eur Urol. 2013 Aug;64(2):e29-30. doi: 10.1016/j.eururo.2013.04.015. Epub 2013 Apr 19.</citation>
    <PMID>23619389</PMID>
  </results_reference>
  <results_reference>
    <citation>Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.</citation>
    <PMID>24321502</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2017</study_first_submitted>
  <study_first_submitted_qc>April 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 2, 2017</study_first_posted>
  <last_update_submitted>April 29, 2017</last_update_submitted>
  <last_update_submitted_qc>April 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>Reham Algahndour</investigator_full_name>
    <investigator_title>Assistant lecturer</investigator_title>
  </responsible_party>
  <keyword>Metformin, prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

